Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 5/20 | 0.51 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20805183 | 0.88 | GRM5 (0.45) | TLR9TLR7MAOBBRD4 | |
| SCHEMBL5757160 | 0.81 | CYP1A2 (0.49) | MAOB | |
| SCHEMBL6452344 | 0.77 | TLR9 (0.51) | TLR9TLR7SYKMAOBCYP11B1 | |
| SCHEMBL27647848 | 0.76 | NPC1 (0.65) | MAOB | |
| SCHEMBL5758416 | 0.75 | TLR9 (0.44) | TLR9TLR7 | |
| SCHEMBL22498619 | 0.73 | TLR9 (0.46) | TLR9TLR7L3MBTL1BRD4HDAC8 | |
| SCHEMBL22520499 | 0.73 | TLR9 (0.48) | TLR9TLR7MAOBBRD4 | |
| SCHEMBL12772071 | 0.72 | MAOB (0.62) | MAOBABCB1HTR1ADRD2HDAC8 | |
| SCHEMBL13791570 | 0.72 | MAOB (0.62) | MAOBABCB1L3MBTL1HTR1ADRD2 | |
| SCHEMBL1179955 | 0.72 | CYP1A2 (0.55) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | TLR9 568/4885TLR7 190/4885SYK 4072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.